Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $140000.0.

  • Keros Therapeutics' Cash from Financing Activities fell 9991.02% to $140000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year decrease of 8036.34%. This contributed to the annual value of $391.8 million for FY2024, which is 11894.82% up from last year.
  • As of Q3 2025, Keros Therapeutics' Cash from Financing Activities stood at $140000.0, which was down 9991.02% from $17000.0 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Cash from Financing Activities ranged from a high of $156.8 million in Q1 2024 and a low of $4000.0 during Q1 2025
  • Its 5-year average for Cash from Financing Activities is $37.9 million, with a median of $3.5 million in 2024.
  • As far as peak fluctuations go, Keros Therapeutics' Cash from Financing Activities surged by 13870857.14% in 2022, and later tumbled by 9999.74% in 2025.
  • Over the past 5 years, Keros Therapeutics' Cash from Financing Activities (Quarter) stood at $28.4 million in 2021, then skyrocketed by 116.13% to $61.4 million in 2022, then increased by 12.76% to $69.3 million in 2023, then rose by 9.08% to $75.5 million in 2024, then tumbled by 99.81% to $140000.0 in 2025.
  • Its Cash from Financing Activities stands at $140000.0 for Q3 2025, versus $17000.0 for Q2 2025 and $4000.0 for Q1 2025.